Distinct functions of opioid-related peptides and gastrin-releasing peptide in regulating itch and pain in the spinal cord of primates

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Lee, Heeseung ^a   Ko, Mei Chuan ^b  

^a Ewha Womans University School of Medicine   (South Korea)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ENDORPHIN; DYNORPHIN; GASTRIN RELEASING PEPTIDE; NARCOTIC ANALGESIC AGENT; NEUROPEPTIDE;

ANIMAL; ANIMAL BEHAVIOR; COMPLICATION; DRUG EFFECTS; FEMALE; HYPERALGESIA; INTRASPINAL DRUG ADMINISTRATION; MALE; METABOLISM; PAIN; PATHOLOGY; PRURITUS; RHESUS MONKEY; SPINAL CORD;

ANALGESICS, OPIOID; ANIMALS; BEHAVIOR, ANIMAL; BETA-ENDORPHIN; DYNORPHINS; FEMALE; GASTRIN-RELEASING PEPTIDE; HYPERALGESIA; INJECTIONS, SPINAL; MACACA MULATTA; MALE; NEUROPEPTIDES; PAIN; PRURITUS; SPINAL CORD;

EID: 84934275739     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep11676     Document Type: Article

References (48)

1. Yosipovitch, G. & Bernhard, J. D. Clinical practice. Chronic pruritus. N Engl J Med 368, 1625-1634 (2013).
2. Bergasa, N. V. Pruritus in primary biliary cirrhosis: pathogenesis and therapy. Clin Liver Dis 12, 385-406; x (2008).
3. Kfoury, L. W. & Jurdi, M. A. Uremic pruritus. J Nephrol 25, 644-652 (2012).
4. Terg, R., Coronel, E., Sorda, J., Munoz, A. E. & Findor, J. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol 37, 717-722 (2002).
5. Bergasa, N. V., Thomas, D. A., Vergalla, J., Turner, M. L. & Jones, E. A. Plasma from patients with the pruritus of cholestasis induces opioid receptor-mediated scratching in monkeys. Life Sci 53, 1253-1257 (1993).
6. Bodnar, R. J. Endogenous opiates and behavior: 2013. Peptides 62, 67-136 (2014).
7. Ko, M. C. & Naughton, N. N. An experimental itch model in monkeys: characterization of intrathecal morphine-induced scratching and antinociception. Anesthesiology 92, 795-805 (2000).
8. Ko, M. C. & Husbands, S. M. Effects of atypical kappa-opioid receptor agonists on intrathecal morphine-induced itch and analgesia in primates. J Pharmacol Exp Ther 328, 193-200 (2009).
9. Ganesh, A. & Maxwell, L. G. Pathophysiology and management of opioid-induced pruritus. Drugs 67, 2323-2333 (2007).
10. Todd, A. J. Neuronal circuitry for pain processing in the dorsal horn. Nat Rev Neurosci 11, 823-836 (2010).
11. Bautista, D. M., Wilson, S. R. & Hoon, M. A. Why we scratch an itch: the molecules, cells and circuits of itch. Nat Neurosci 17, 175-182 (2014).
12. LaMotte, R. H., Dong, X. & Ringkamp, M. Sensory neurons and circuits mediating itch. Nat Rev Neurosci 15, 19-31 (2014).
13. Jensen, R. T., Battey, J. F., Spindel, E. R. & Benya, R. V. International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. Pharmacol Rev 60, 1-42 (2008).
14. Masui, A. et al. Scratching behavior induced by bombesin-related peptides. Comparison of bombesin, gastrin-releasing peptide and phyllolitorins. Eur J Pharmacol 238, 297-301 (1993).
15. Sun, Y. G. & Chen, Z. F. A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord. Nature 448, 700-703 (2007).
16. Nattkemper, L. A. et al. Overexpression of the gastrin-releasing peptide in cutaneous nerve fibers and its receptor in the spinal cord in primates with chronic itch. J Invest Dermatol 133, 2489-2492 (2013).
17. Kagami, S. et al. Serum gastrin-releasing peptide levels correlate with pruritus in patients with atopic dermatitis. J Invest Dermatol 133, 1673-1675 (2013).
18. Courtine, G. et al. Can experiments in nonhuman primates expedite the translation of treatments for spinal cord injury in humans? Nat Med 13, 561-566 (2007).
19. Lin, A. P. & Ko, M. C. The therapeutic potential of nociceptin/orphanin FQ receptor agonists as analgesics without abuse liability. ACS Chem Neurosci 4, 214-224 (2013).
20. Phillips, K. A. et al. Why primate models matter. Am J Primatol 76, 801-827 (2014).
21. Imamachi, N. et al. TRPV1-expressing primary afferents generate behavioral responses to pruritogens via multiple mechanisms. Proc Natl Acad Sci USA 106, 11330-11335 (2009).
22. Gibson, R. A. et al. A randomised trial evaluating the effects of the TRPV1 antagonist SB705498 on pruritus induced by histamine, and cowhage challenge in healthy volunteers. PLoS One 9, e100610 (2014).
23. Lee, H., Naughton, N. N., Woods, J. H. & Ko, M. C. Characterization of scratching responses in rats following centrally administered morphine or bombesin. Behav Pharmacol 14, 501-508 (2003).
24. Sukhtankar, D. D. & Ko, M. C. Physiological function of gastrin-releasing peptide and neuromedin B receptors in regulating itch scratching behavior in the spinal cord of mice. PLoS One 8, e67422 (2013).
25. Lee, H., Naughton, N. N., Woods, J. H. & Ko, M. C. Effects of butorphanol on morphine-induced itch and analgesia in primates. Anesthesiology 107, 478-485 (2007).
26. Wu, Z., Kong, M., Wang, N., Finlayson, R. J. & Tran, Q. H. Intravenous butorphanol administration reduces intrathecal morphine-induced pruritus after cesarean delivery: a randomized, double-blind, placebo-controlled study. J Anesth 26, 752-757 (2012).
27. Hu, E., Calo, G., Guerrini, R. & Ko, M. C. Long-lasting antinociceptive spinal effects in primates of the novel nociceptin/orphanin FQ receptor agonist UFP-112. Pain 148, 107-113 (2010).
28. Ko, M. C., Wei, H., Woods, J. H. & Kennedy, R. T. Effects of intrathecally administered nociceptin/orphanin FQ in monkeys: behavioral and mass spectrometric studies. J Pharmacol Exp Ther 318, 1257-1264 (2006).
29. Herman, B. H. & Goldstein, A. Antinociception and paralysis induced by intrathecal dynorphin A. J Pharmacol Exp Ther 232, 27-32 (1985).
30. Ko, M. C. et al. Activation of kappa-opioid receptors inhibits pruritus evoked by subcutaneous or intrathecal administration of morphine in monkeys. J Pharmacol Exp Ther 305, 173-179 (2003).
31. Sukhtankar, D. D., Lee, H., Rice, K. C. & Ko, M. C. Differential effects of opioid-related ligands and NSAIDs in nonhuman primate models of acute and inflammatory pain. Psychopharmacology (Berl) 231, 1377-1387 (2014).
32. Alt, A. et al. Stimulation of guanosine-5-O-(3-[35S]thio)triphosphate binding by endogenous opioids acting at a cloned mu receptor. J Pharmacol Exp Ther 286, 282-288 (1998).
33. Kenakin, T. Drug efficacy at G protein-coupled receptorreceptors. Annu Rev Pharmacol Toxicol 42, 349-379 (2002).
34. Ko, M. C., Song, M. S., Edwards, T., Lee, H. & Naughton, N. N. The role of central mu opioid receptors in opioid-induced itch in primates. J Pharmacol Exp Ther 310, 169-176 (2004).
35. Liu, X. Y. et al. Unidirectional cross-Activation of GRPR by MOR1D uncouples itch and analgesia induced by opioids. Cell 147, 447-458 (2011).
36. Peckys, D. & Landwehrmeyer, G. B. Expression of mu, kappa, and delta opioid receptor messenger RNA in the human CNS: a 33P in situ hybridization study. Neuroscience 88, 1093-1135 (1999).
37. Peng, J., Sarkar, S. & Chang, S. L. Opioid receptor expression in human brain and peripheral tissues using absolute quantitative real-Time RT-PCR. Drug Alcohol Depend 124, 223-228 (2012).
38. Calo, G. & Guerrini, R. Medicinal chemistry, pharmacology, and biological actions of peptide ligands selective for the nociceptin/ orphanin FQ receptor. in Research and Development of Opioid-Related Ligands, ACS Symposium Series 1131 (eds. Ko, M. C. & Husbands, S. M.) 275-325 (American Chemical Society, Washington DC, USA, 2013).
39. Schroder, W., Lambert, D. G., Ko, M. C. & Koch, T. Functional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists. Br J Pharmacol 171, 3777-3800 (2014).
40. Monteillet-Agius, G., Fein, J., Anton, B. & Evans, C. J. ORL-1 and mu opioid receptor antisera label different fibers in areas involved in pain processing. J Comp Neurol 399, 373-383 (1998).
41. Su, P. Y. & Ko, M. C. The role of central gastrin-releasing peptide and neuromedin B receptors in the modulation of scratching behavior in rats. J Pharmacol Exp Ther 337, 822-829 (2011).
42. Goswami, S. C. et al. Itch-Associated peptides: RNA-Seq and bioinformatic analysis of natriuretic precursor peptide B and gastrin releasing peptide in dorsal root and trigeminal ganglia, and the spinal cord. Mol Pain 10, 44 (2014).
43. Inan, S. & Cowan, A. Reduced kappa-opioid activity in a rat model of cholestasis. Eur J Pharmacol 518, 182-186 (2005).
44. Kardon, A. P., et al. Dynorphin acts as a neuromodulator to inhibit itch in the dorsal horn of the spinal cord. Neuron 82, 573-586 (2014).
45. Gmerek, D. E. & Cowan, A. In vivo evidence for benzomorphan-selective receptors in rats. J Pharmacol Exp Ther 230, 110-115 (1984).
46. Butelman, E. R., Negus, S. S., Ai, Y., de Costa, B. R. & Woods, J. H. Kappa opioid antagonist effects of systemically administered nor-binaltorphimine in a thermal antinociception assay in rhesus monkeys. J Pharmacol Exp Ther 267, 1269-1276 (1993).
47. Ko, M. C. et al. Intracisternal nor-binaltorphimine distinguishes central and peripheral kappa-opioid antinociception in rhesus monkeys. J Pharmacol Exp Ther 291, 1113-1120 (1999).
48. Kumagai, H. et al. Efficacy and safety of a novel k-Agonist for managing intractable pruritus in dialysis patients. Am J Nephrol 36, 175-183 (2012).